Sierra Oncology Inc (SRRA)
Sierra Oncology is a late-stage biopharmaceutical company focused on therapies that treat cancer. Co.'s focus is the development and commercialization of momelotinib, an investigational agent for the treatment of myelofibrosis. Momelotinib is a small-molecule inhibitor of JAK1 (Janus kinase 1), JAK2 (Janus kinase 2) and ACVR1 (Activin A receptor type 1), under development for treatment of patients with myelofibrosis. Co. has conducted a review of data from the two Phase 3 trials of momelotinib, versus ruxolitinib and best available therapy, as well as GS-US-352-1672, a Phase 2, open-label, translational biology trial of momelotinib in transfusion-dependent subjects with myelofibrosis.
|
April 26, 2024 4:38 AM Eastern
Hold (2.00 out of 4)
100th percentile
|
|